Circulation, Vol 71, 317-325, Copyright © 1985 by American Heart Association
P Daly, B Mettauer, JL Rouleau, D Cousineau and JH Burgess
Many vasodilators have been tried as antianginal agents, but the reflex
increase in sympathetic tone produced by these drugs necessitate their use
with caution in patients with angina. In the first part of this study,
captopril was given to 14 patients with angina and systolic arterial
pressures of greater than 120 mm Hg. Over the short term, captopril
decreased arterial blood pressure (from 110 +/- 18 to 98 +/- 18 mm Hg, p
less than .01) without increasing heart rate (75 +/- 15 vs 74 +/- 15
beats/min), arterial concentrations of epinephrine (0.38 +/- 0.28 vs 0.34
+/- 0.25 nM) or norepinephrine (2.7 +/- 2.1 vs 2.8 +/- 2.1 nM), or
transmyocardial norepinephrine balance (216 +/- 254 vs 146 +/- 170 p
mol/min). Captopril decreased average myocardial oxygen consumption (9.7
+/- 4.1 to 8.2 +/- 2.7 ml/min, p less than .01). Given over the long term
(mean 5.5 months), captopril decreased the severity of angina from NYHA
classification 3.0 +/- 0.8 to 1.6 +/- 0.8. In the second part of this
study, captopril was given in a prospective, randomized, double-blind,
placebo-controlled study to 21 patients with stable exercise-induced angina
and systolic arterial pressures greater than 120 mm Hg. Captopril increased
exercise time (309 +/- 137 vs 374 +/- 142 sec, p less than .05) without
changing anginal threshold (rate- pressure product 17.0 +/- 6.0 vs 17.1 +/-
5.6 X 10(-3)). We conclude that captopril decreases mean arterial pressure
without causing a reflex increase in myocardial sympathetic tone.(ABSTRACT
TRUNCATED AT 250 WORDS)
ARTICLES
Lack of reflex increase in myocardial sympathetic tone after captopril: potential antianginal effect
This article has been cited by other articles:
![]() |
C. J. Pepine, J.-L. Rouleau, K. Annis, A. Ducharme, P. Ma, J. Lenis, R. Davies, U. Thadani, B. Chaitman, H. E. Haber, et al. Effects of angiotensin-converting enzyme inhibition on transient ischemia: The quinapril anti-ischemia and symptoms of angina reduction (QUASAR) trial J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2049 - 2059. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Prasad, R. Mincemoyer, and A. A. Quyyumi Anti-ischemic effects of angiotensin- converting enzyme inhibition in hypertension J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1116 - 1122. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. M. van den Heuvel, P. H. J. M. Dunselman, T. Kingma, P. Verhorst, F. Boomsma, W. H. van Gilst, and D. J. van Veldhuisen Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade J. Am. Coll. Cardiol., February 1, 2001; 37(2): 470 - 474. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1985 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |